Two thirds of these novel targeted anticancer agents inhibit kinases, including EGFR, Src, and mammalian target of rapamycin (mTOR) activated in cancer cells as well as in microenvironment cells and now several V-ATPases inhibitors are under trial. The gene discussed is SRC; the disease is cancer.